Canine

Escherichia coli.

Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

APTRSPTLVT RPSQHVDAIQ EALSLLNNSN DVTAVMNKAV KVVSEVFDPE GPTCLETRLQ LYKEGLQGSL TSLKNPLTMM ANHYKQHCPP TPESPCATQN INFKSFKENL KDFLFNIPFD CWKPVKK

> 95 % by SDS-PAGE and HPLC analyses.

Less than 1 EU/μg of rCaGM-CSF as determined by LAL method.

Fully biologically active when compared to standard. The ED₅₀ as determined by a cell proliferation assay using human TF-1 cells is less than 5 ng/ml, corresponding to a specific activity of > 2.0 × 10⁵ IU/mg.

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.

1. Wang JM, Chen ZG, Colotta F, et al. 1988. Behring Inst Mitt: 270-3.
2. 1989. N Engl J Med, 320: 253-4.
3. Nissen-Druey C. 1989. Nouv Rev Fr Hematol, 31: 99-101.
4. Eager RandNemunaitis J. 2005. Mol Ther, 12: 18-27.
5. Tran T, Fernandes DJ, Schuliga M, et al. 2005. Br J Pharmacol, 145: 123-31.